Lekander, Ingrid; Borgström, Fredrik; Lysholm, Jörgen; … - In: The European Journal of Health Economics 14 (2013) 6, pp. 863-873
These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator. </AbstractSection> Copyright Springer-Verlag 2013